cc-90001
Small moleculeexperimental
Clinical trial activity
10 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2014 (NCT02110420)
Timeline
Indications
Studied for
- Fibrosis · Phase 2
- Healthy Volunteers · Phase 1
- Idiopathic Interstitial Pneumonias · Phase 2
- Idiopathic Pulmonary Fibrosis · Phase 2
- Liver Cirrhosis · Phase 2
- Liver Diseases · Phase 1
- Lung Diseases · Phase 2
- Lung Diseases, Interstitial · Phase 2
- Neoplasms · Phase 1
- Non-alcoholic Fatty Liver Disease · Phase 2
- Pathologic Processes · Phase 2
- Pulmonary Fibrosis · Phase 1
- Respiratory Tract Diseases · Phase 2
- Volunteers · Phase 1
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H]1CC[C@@H](Nc2nc(NC(C)(C)C)ncc2C(N)=O)C[C@H]1O- Mol. weight
- 321.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4847106 ↗
Also known as
- cc-90001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05625412 | Phase 1 | Dec 9, 2022 | Bristol-Myers Squibb |
| NCT04655898 | Phase 1 | Dec 16, 2020 | Bristol-Myers Squibb, Celgene |
| NCT04048876 | Phase 2 | Aug 7, 2019 | Celgene |
| NCT03958864 | Phase 1 | Apr 4, 2019 | Celgene |
| NCT03742882 | Phase 1 | Dec 15, 2018 | Celgene |
| NCT03363815 | Phase 1 | Dec 4, 2017 | Celgene |
| NCT03142191 | Phase 2 | May 5, 2017 | Celgene |
| NCT02510937 | Phase 1 | Aug 5, 2015 | Celgene |
| NCT02321644 | Phase 1 | Nov 1, 2014 | Celgene |
| NCT02110420 | Phase 1 | Feb 1, 2014 | Celgene |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 9 | 9 | 2 | 2014 |
| Bristol-Myers Squibb | For profit | 2 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1